Pao Ling Fu Chin Biotech Co., Ltd.: Q1 2026 EPS 0.60 NTD
Key facts
- Pao Ling Fu Chin Biotech Co., Ltd.: Q1 2026 EPS 0.60 NTD
- Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.
- Source: PR Times
- Date: March 1, 2026
Direct answer
Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.
- Citation
- Pao Ling Fu Chin Biotech Co., Ltd.: Q1 2026 EPS 0.60 NTD (March 1, 2026), PR Times
- Source
- PR Times
- Date
- March 1, 2026
Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 14, 2026 at 08:00 (1775h 0m after Published)
- 🤖 AI Analyzed: May 14, 2026 at 08:29 (29 min after Collected)
Company Name: Pao Ling Fu Chin Biotech Co., Ltd.
Industry: Biotechnology and Medical Industry
Year/Quarter: Q1 2026
Basic Earnings Per Share (EPS): 0.60 NTD
Operating Revenue: 519 million NTD
Net Income After Tax: 52 million NTD
FAQ
What are the key facts in this article?
Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.
What is the direct answer?
Pao Ling Fu Chin Biotech Co., Ltd. reported a stable performance in Q1 2026, with an EPS of 0.60 NTD, operating revenue of 519 million NTD, and net income after tax of 52 million NTD. This reaffirms its position in the biotechnology and medical industry.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-1760-2026Q1 | March 1, 2026